A retrospective study on the use of heparin for peripheral vascular intervention

Perspectives in Vascular Surgery and Endovascular Therapy

Volumn 24, Issue 2, 2012, Pages 63-69

  Walker, Stuart ^a   Beasley, Charles ^a   Reeves, Mark ^b  

^a ROYAL HOBART HOSPITAL   (Australia)

^b North West Regional Hospital   (Australia)

Author keywords

angioplasty; anticoagulation; peripheral stent

Indexed keywords

HEPARIN;

ADULT; AGED; ARTICLE; COMPRESSION THERAPY; CONTROLLED STUDY; EMBOLISM; FEMALE; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RETROPERITONEAL HEMATOMA; RETROSPECTIVE STUDY; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY; ANTICOAGULANTS; EMBOLISM; FEMALE; HEMORRHAGE; HEMOSTATIC TECHNIQUES; HEPARIN; HUMANS; LOGISTIC MODELS; LOWER EXTREMITY; MALE; MIDDLE AGED; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872149589     PISSN: 15310035     EISSN: 15310027     Source Type: Journal    
DOI: 10.1177/1531003512459889     Document Type: Article

References (13)

1. Dotter CT, Judkins MP. Transluminal treatment of atheriosclerotic obstruction: description of a new technique and preliminary report of its application. Circulation. 1964 ; 30: 654-670
2. Fuster V, Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ. The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thromb Haemost. 1995 ; 74: 552-559
3. Tsakiris DA, Tschöpl M, Jäger K, Haefeli WE, Wolf F, Marbet GA. Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis. 1999 ; 142: 193-200
4. Lam RC, Shah S, Faries PL, McKinsey JF, Kent KC, Morrissey NJ. Incidence and clinical significance of distal embolization during percutaneous interventions involving the superficial femoral artery. J Vasc Surg. 2007 ; 46: 1155-1159
5. Miller DL. Heparin in angiography: current patterns of use. Radiology. 1989 ; 172: 1007-1011
6. Mulry CC, Le Veen RF, Sobel M, Lampe PJ, Burke DR. Assessment of heparin anticoagulation during peripheral angioplasty. J Vasc Interv Radiol. 1991 ; 2: 133-139
7. Zaman SM, de Vroos Meiring P, Gandhi MR, Gaines PA. The pharmacokinetics and UK usage of heparin in vascular intervention. Clin Radiol. 1996 ; 51: 113-116
8. Moussa O, Jonker L, Joseph T. Marked variation in venous thromboprophylaxis management for abdominal aortic aneurysm repair; results of survey amongst vascular surgeons in the United Kingdom. Eur J Vasc Endovasc Surg. 2011 ; 42: 591-595
9. Shammas NW, Shammas GA, Jerin M, Dippel EJ, Shammas AN. In-hospital safety and effectiveness of bivalirudin in percutaneous peripheral interventions: data from a real-world registry. J Endovasc Ther. 2010 ; 17: 31-36
10. Sheikh IR, Ahmed SH, Mori N, et al. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in percutaneous peripheral intervention: a single-centre experience. JACC Cardiovasc Interv. 2009 ; 2: 871-876
11. Shammas NW, Lemke JH, Dippel EJ, et al. In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant. J Invasive Cardiol. 2003 ; 15: 242-246
12. Wheatley BJ, Mansour MA, Grossman PM, et al. Complication rates for percutaneous lower extremity arterial antegrade access. Arch Surg. 2011 ; 146: 432-435
13. Hanna N, Fiorilli P, Gaglia MA, et al. Low-dose protamine to facilitate earlier sheath removal from the femoral artery after peripheral endovascular intervention. J Interv Cardiol. 2011 ; 24: 278-284